Danish Alk-Abello has reached the primary endpoint in a Phase 3 study of the allergy tablet ACARIZAX for house dust mites in China. The study included 327 patients and showed 19.1 percent better efficacy than placebo after 24–28 weeks of treatment.
The effect could be demonstrated after just eight weeks. The treatment also showed a favorable safety profile. ALK and its partner GenSci plan to apply for marketing approval in China during the first half of 2027. The results do not affect the company’s 2026 forecast.